Morning Briefing
Summaries of health policy coverage from major news organizations
Bloomberg Examines Potential Benefits, Drawbacks To PrEP
"Gilead Sciences Inc. may learn this year whether its drugs for treating HIV can also stop people from catching the virus in the first place," Bloomberg writes in a piece that examines the potential benefits and drawbacks to using low-doses of HIV/AIDS medications to reduce a person's risk of becoming infected with HIV. According to the news service, the initial results of 10 trials including more than 20,000 people could be available as early as July.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
